Lessons from times of shortage: Interchangeability of venom preparations and dosing protocols
Corresponding Author
Johanna Stoevesandt
Department of Dermatology, Venereology, and Allergology, Allergy Center Mainfranken, University Hospital Würzburg, Würzburg, Germany
Correspondence
Johanna Stoevesandt, Department of Dermatology, Venereology, and Allergology, Allergy Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.
Email: [email protected]
Search for more papers by this authorAxel Trautmann
Department of Dermatology, Venereology, and Allergology, Allergy Center Mainfranken, University Hospital Würzburg, Würzburg, Germany
Search for more papers by this authorCorresponding Author
Johanna Stoevesandt
Department of Dermatology, Venereology, and Allergology, Allergy Center Mainfranken, University Hospital Würzburg, Würzburg, Germany
Correspondence
Johanna Stoevesandt, Department of Dermatology, Venereology, and Allergology, Allergy Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.
Email: [email protected]
Search for more papers by this authorAxel Trautmann
Department of Dermatology, Venereology, and Allergology, Allergy Center Mainfranken, University Hospital Würzburg, Würzburg, Germany
Search for more papers by this author
Supporting Information
| Filename | Description |
|---|---|
| all13739-sup-0001-FigS1.pdfPDF document, 167.3 KB | |
| all13739-sup-0002-TableS1.docxWord document, 16.1 KB | |
| all13739-sup-0003-Legends.docxWord document, 14 KB |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Golden DB, Bernstein DI, Freeman TM, Tracy JM, Lang DM, Nicklas RA. AAAAI/ACAAI joint venom extract shortage task force report. J Allergy Clin Immunol Pract. 2017; 5(2): 330-332.
- 2Stoevesandt J, Hosp C, Kerstan A, Trautmann A. Safety of 100 μg venom immunotherapy rush protocols in children compared to adults. Allergy Asthma Clin Immunol. 2017; 13: 32.
- 3Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy. Allergy. 2018; 73(4): 744-764.
- 4Alfaya Arias T, Soriano Gómis V, Soto Mera T, et al. Key issues in hymenoptera venom allergy: an update. J Investig Allergol Clin Immunol. 2017; 27(1): 19-31.
- 5Blank S, Etzold S, Darsow U, et al. Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy. Hum Vaccin Immunother. 2017; 13(10): 2482-2489.
- 6Bilò MB, Antonicelli L, Bonifazi F. Purified vs. nonpurified venom immunotherapy. Curr Opin Allergy Clin Immunol. 2010; 10(4): 330-336.
- 7Bilò MB, Severino M, Cilia M, et al. The VISYT trial: venom immunotherapy safety and tolerability with purified vs nonpurified extracts. Ann Allergy Asthma Immunol. 2009; 103(1): 57-61.
- 8Brehler R, Wolf H, Kütting B, Schnitker J, Luger T. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol. 2000; 105(6 Pt 1): 1231-1235.
- 9Worm M. Verträglichkeit der spezifischen Immuntherapie während der Umstellung von lyophilisiertem Wespengift auf ein Depotpräparat. Allergologie. 2009; 32(4): 143-145.
10.5414/ALP32143 Google Scholar
Citing Literature
